How many acquisitions has Novartis made so far?

Novartis has completed 44 acquisitions so far, with an average acquisition amount of $3.07B.

Which countries does Novartis usually acquire in?

Novartis has made acquisitions in 7 countries with the most activity in United States and United Kingdom.

Which sectors does Novartis target for acquisitions?

Most of Novartis's acquisitions are in Oncology (10) and Immunotherapy (8).

In which year did Novartis make the most acquisitions?

Novartis was most active in 2024, with 5 acquisitions completed in that year.

List of 44 Acquisitions by Novartis (Apr 2026)

Q: Which is Novartis' latest acquisition?

Novartis's most recent acquisition is Excellergy, a Developer of trifunctional effector cell response inhibitors for allergic diseases, acquired in March 2026 for $2B.

Novartis has completed a total of 44 acquisitions. Peak acquisition activity occurred in 2024 with 5 acquisitions, 2016 with 5 acquisitions, and 2025 with 4 acquisitions. These acquisitions span 7 countries, including United States (29), United Kingdom (4), and Switzerland (3), and cover 24 sectors, with significant activity in Oncology (10), Immunotherapy (8), and Ophthalmology (7). Over the last five years (2020–2025), the average number of acquisitions per year was 2.8. So far this calendar year, 1 acquisition has been completed. The most recent acquisition was Excellergy, a developer of trifunctional effector cell response inhibitors for allergic diseases. Founded in 2020 and located in Palo Alto, this acquisition was completed in March 2026 for $2B.

Here's the year on year acquisition history of Novartis:

Number of Total Acquisitions

Year	# Acquisitions
2026	1
2025	4
2024	5
2023	2
2022	1
2021	2
2020	3
2019	2
2018	2
2017	1
2016	5
2015	2
2014	1
2012	1
2011	1
2010	1
2009	2
2008	2
2006	2
2005	2
2002	1
1997	1

View all Acquisitions by Novartis

Recent acquisitions by Novartis

Novartis's most recent acquisition - Excellergy is a Developer of trifunctional effector cell response inhibitors for allergic diseases, founded in 2020 and located in Palo Alto. Novartis acquired it in March 2026 for a price of $2B.

Here is the list of all acquisitions by Novartis sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Mar 27, 2026	Excellergy	$2B	-	83	429
Oct 27, 2025	Avidity Biosciences	$12B	Homburger	69	110
Sep 09, 2025	Tourmaline Bio	$1.4B	Leerink Partners	81	132
Apr 30, 2025	Regulus Therapeutics	$1.7B	-	67	239
Feb 11, 2025	Anthos Therapeutics	$3.1B	Goodwin, Morgan Stanley ... and 1 more	18	443